Poster Presentations / Osteoarthritis and Cartilage 19S1 (2011) S53-S236 S207 consistently associated with measures of function and disability. Most closely associated with function measures were: pain affecting sleep, for WOMAC function; pain catastrophizing, for Late Life basic function, chair stand time, and disability; and pain after 20 m walk, for Late Life advanced function. These findings suggest that different aspects of the pain experience in knee OA may have unique relationships with function and disability. Ultimately, specific multidisciplinary attention to aspects such as the impact of pain on sleep and pain catastrophizing may be a more meaningful approach for the person with painful knee OA, and potentially have greater impact on function and disability over time. (OA DSP VII, 2008). Methods: OA severity was rated by patients based on the question "How bad would you say your arthritis is now?" with potential responses of "mild," "moderate," and "severe." Other patient-reported outcomes included; a pain visual analogue scale (0 = no pain, 100 = worst possible pain); questions on activities of daily living (1 = no difficulty, 2 = some difficulty, 3 = much difficulty, 4 = unable to do); and the EuroQol health status instrument (EQ-5D). Data on productivity were captured using the Work Productivity and Activity Impairment scale (WPAI). Associations between OA severity and other outcomes were evaluated using descriptive and regression analyses. Results: Data were available from 1739 patients (63.1% female, mean age 64 years) from France, Germany, Italy, Spain, and the United Kingdom. OA severity was rated as mild, moderate and severe by 24.5%, 56.4%, and 19.2% of the patients, respectively. There was an overall association between patient-rated OA severity and age (p < 0.05). Greater patientreported OA severity was associated with higher pain scores; 28.3, 49.9, and 69.2 for mild, moderate and severe OA, respectively (p < 0.05 for pairwise comparisons). As patient-reported OA severity increased, so did functional impairment as indicated by greater difficulty in performing 9 basic and 3 instrumental activities of daily living. After adjustment for gender, the difficulty score was greater than 1 at each OA severity level for every item of functional ability (lower bounds of the 95% confidence intervals were greater than 1); the greatest difficulty was observed among patients who reported severe OA. Pairwise comparisons between OA severity levels showed that differences in functional abilities were statistically significant (p < 0.05). Decreases in patient-reported health status with increasing OA severity were also observed on the EQ-5D health state VAS, and the health state index; 0.77, 0.62, and 0.30 for mild, moderate, and severe OA, respectively (p < 0.0001 for all pairwise comparisons). Among the 425 patients who were employed, the percent of OA-related impairment of work and activity increased at greater OA severity levels after adjusting for age and gender; higher costs resulting from lost productivity were also observed with increasing OA severity (p < 0.0001 for pairwise comparisons). Conclusions: Patient-reported OA severity was associated with other patient-reported outcomes, including productivity, and these outcomes were most impacted in patients with severe OA. This method provides an accurate and tangible assessment of patient's perceptions of their disease, and may be of benefit in the clinical setting when choosing treatment options for management of OA. Purpose: Osteoarthritis (OA) is characterized by joint pain, stiffness, and inflammation and can be associated with a significant number of comorbid conditions. In this retrospective longitudinal study, we estimated the rate of hip and knee replacement surgery in patients with OA and characterized joint replacement, pain medication treatment patterns, and concomitant gastroprotective agent (GPA) use. Methods: Data were enrollment information and medical and pharmacy claims data from a large, national US health plan. The study population was adult (age ≥18 years) commercial health plan enrollees newly diagnosed with OA during the identification period 1/1/2000-4/30/2009. Patients had ≥2 medical claims with primary OA diagnoses 721.0, 721.2, 721.3, 721.90) ≥30 days apart in the identification period; the index date was the date of the first OA diagnosis. Patients had 1 year of pre-index continuous enrollment with no chronic use of NSAIDs, COX-2 inhibitors (coxibs), or oral opioids, and ≥1 year of postindex enrollment. Outcomes included hip and knee replacement surgery and pain medication use. Demographics, comorbidities, and Charlson Comorbidity Index (CCI) score were measured. Data were analyzed descriptively. Results: Of 193,829 newly diagnosed patients with OA, 57% were female and 43% were male. Patients whose first observed chronic pain medication use (index pain medications) were strong opioids appeared to have a higher mean CCI score, 1.16, compared with those with NSAIDs, coxibs, and weak opioid index pain medications (0.53-0.83). Patients in the youngest (18-44) and oldest (75+) age groups appeared to be more likely to have an opioid (35.7% and 34.9% respectively) as their index pain medication compared with patients in the middle age groups (45-54 yrs: 24.5%, 55-64 yrs: 19.9%, 65-74 yrs: 24.0%). The incident rates of hip or knee replacement per person-year appeared to be higher for those patients with opioids as their index pain medications (0.0663, weak opioids; 0.0801, strong opioids; 0.0464, NSAIDS; 0.0548, coxibs). The mean time from index pain medication to ANY joint replacement appeared shorter for patients whose index pain medications were opioids (106 days, weak opioids; 28 days, strong opioids; 320 days, nonselective NSAIDs; 479 days, coxibs). Only 18% of patients prescribed NSAIDs were co-prescribed a GPA.
Purpose: Osteoarthritis (OA) is characterized by joint pain, stiffness, and inflammation and can be associated with a significant number of comorbid conditions. In this retrospective longitudinal study, we estimated the rate of hip and knee replacement surgery in patients with OA and characterized joint replacement, pain medication treatment patterns, and concomitant gastroprotective agent (GPA) use. Methods: Data were enrollment information and medical and pharmacy claims data from a large, national US health plan. The study population was adult (age ≥18 years) commercial health plan enrollees newly diagnosed with OA during the identification period 1/1/2000-4/30/2009. Patients had ≥2 medical claims with primary OA diagnoses 721.0, 721.2, 721.3, 721 .90) ≥30 days apart in the identification period; the index date was the date of the first OA diagnosis. Patients had 1 year of pre-index continuous enrollment with no chronic use of NSAIDs, COX-2 inhibitors (coxibs), or oral opioids, and ≥1 year of postindex enrollment. Outcomes included hip and knee replacement surgery and pain medication use. Demographics, comorbidities, and Charlson Comorbidity Index (CCI) score were measured. Data were analyzed descriptively. Results: Of 193,829 newly diagnosed patients with OA, 57% were female and 43% were male. Patients whose first observed chronic pain medication use (index pain medications) were strong opioids appeared to have a higher mean CCI score, 1.16, compared with those with NSAIDs, coxibs, and weak opioid index pain medications (0.53-0.83). Patients in the youngest (18-44) and oldest (75+) age groups appeared to be more likely to have an opioid (35.7% and 34.9% respectively) as their index pain medication compared with patients in the middle age groups (45-54 yrs: 24.5%, 55-64 yrs: 19.9%, 65-74 yrs: 24.0%). The incident rates of hip or knee replacement per person-year appeared to be higher for those patients with opioids as their index pain medications (0.0663, weak opioids; 0.0801, strong opioids; 0.0464, NSAIDS; 0.0548, coxibs). The mean time from index pain medication to ANY joint replacement appeared shorter for patients whose index pain medications were opioids (106 days, weak opioids; 28 days, strong opioids; 320 days, nonselective NSAIDs; 479 days, coxibs). Only 18% of patients prescribed NSAIDs were co-prescribed a GPA.
Conclusions:
The data from this study indicate specific patterns of relationships between the index diagnosis of OA, joint replacement, pain medication treatment, age, and concomitant GPA use. These data may be important in refining contemporary treatment guidelines, educating physicians in appropriate care paths, and may warrant exploration of potential unmet needs in the management of chronic pain in OA. Purpose: Osteoarthritis (OA) is a degenerative joint disease that is characterized by cartilage destruction and bone changes, occasionally accompanied by synovial inflammation. A major objective for OA research is the conceptualization and development of early diagnostic strategies. The discovery of protein biomarker panels for early diagnosis, therapeutic purposes and management in several diseases is an area of interest in medicine. In the present work we have quantitatively screened differential proteins in sera and cartilage from patients suffering OA at diverse stages. To attain this objective, a quantitative proteomics approach has been followed, which is based on peptide differential
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